Cytokinetics CYTK Total debt
Total debt at other companies
Other financials
Where this comes from
Calculated from Cytokinetics’s reported figures.
Plus components not separately reported this period.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's total debt?
- Cytokinetics (CYTK) reported total debt of $418.21M in Q1 2026.
- How has Cytokinetics's total debt changed year-over-year?
- Cytokinetics's total debt increased by 75.8% year-over-year, from $237.91M to $418.21M.
- What is the long-term trend for Cytokinetics's total debt?
- Over 5 years (2020 to 2025), Cytokinetics's total debt has grown at a 53.0% compound annual growth rate (CAGR), from $49.43M to $414.65M.
- What does total debt mean?
- The total amount of money a company owes to banks, bondholders, and other lenders.
- How do you interpret total debt?
- An increase in total debt suggests higher financial leverage and increased interest expense, which may heighten financial risk for pre-revenue or clinical-stage companies. A decrease indicates deleveraging, potentially improving the balance sheet's resilience against future capital needs.
- How does total debt compare across companies?
- Biotechnology peers often carry varying levels of debt depending on their stage of clinical development and access to capital markets; early-stage firms typically maintain lower debt levels compared to those with commercialized products.